Wuxi Bio, a Chinese CXO company, responds to the suspension of construction at its Worcester base in the United States due to the controversy surrounding the US Biosecurity Act. On the morning of June 18, Wuxi Bio's intra-day stock price fell by more than 3% due to speculation caused by the suspension of construction at its Worcester base. Regarding the progress of the Worcester base in the United States, Wuxi Bio replied to reporters that it was a normal internal adjustment of the company and just a temporary pause. Wuxi Bio did not respond to whether it was related to the controversy surrounding the US Biosecurity Act draft, but only said: "All bases will have design adjustments during the construction process, which is normal operation."
药明生物回应美国伍斯特基地暂停建设
Wuxi Bio, a Chinese CXO company, responds to the suspension of construction at its Worcester base in the United States due to the controversy surrounding the US Biosecurity Act. On the morning of June 18, Wuxi Bio's intra-day stock price fell by more than
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.